SC 13D/A - ImmunityBio, Inc. (0001326110) (Subject)

FORT LAUDERDALE, Fla., June 23, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced the appointment of Sonja Nelson, CPA to the Company's Board of Directors and as Chair of the Audit Committee. Ms. Nelson brings more than 25 years of financial and operational leadership and expertise in biotechnology, diagnostics, and biopharmaceuticals markets, including playing an integral role in the successful merger between NantKwest, Inc. (NASDAQ:NK) an

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley Clark, retired U.S. Army General, to the company’s board of directors, effective immediately. With the appointment of Messrs. Brennan and Clark, the company’s board expands to four directors, including Christobel Selecky, who was appointed to the board in August 2020, and Patrick Soon-Shiong, MD, Chairman and CEO of ImmunityBio. All four directors are expected to serve on the combined board of ImmunityBio and NantKwest (Nasdaq: NK) upon completion of the pending merger. “As we exp

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, today announced that it has appointed Fabio M. Benedetti, M.D., as Chief Strategy Officer, effective January 4, 2021. Dr. Benedetti brings more than 20 years of biotech and large pharma experience in oncology clinical development and medical affairs. In this role, he will oversee life-cycle management, pipeline and commercial strategy, including medical affairs. Following the completion of ImmunityBio’s proposed merger with NantKwest, Dr. Benedetti is expected to assume the role of Chief Strategy Officer of the combined company. “I am pleased to welcome Fabio, a proven leader in clini

FORT LAUDERDALE, Fla., June 23, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced the appointment of Sonja Nelson, CPA to the Company's Board of Directors and as Chair of the Audit Committee. Ms. Nelson brings more than 25 years of financial and operational leadership and expertise in biotechnology, diagnostics, and biopharmaceuticals markets, including playing an integral role in the successful merger between NantKwest, Inc. (NASDAQ:NK) an

CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditions, including approval of the merger by a majority of unaffiliated shareholders of NantKwest at its Special Meeting held on March 8, 2021. The combined company will operate under the name ImmunityBio, Inc. (“ImmunityBio”) and its shares of common stock will commence trading on NASDAQ on March 10, 2021 under the new ticker “IBRX.” “ImmunityBio is the culmination of a decades-long quest to orchestrate natural killer cells

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote each of the proposals related to the pending merger of NantKwest and ImmunityBio, Inc. presented at the special meeting of stockholders held earlier in the day, including approval of the merger by a majority of unaffiliated stockholders of NantKwest. Final voting results for NantKwest’s special meeting of stockholders will be disclosed in a Form 8-K to be filed by NantKwest with the Securities and Exchange Commission. The merger is expected to close on March 9, 2021, subject to the sa

CULVER CITY & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the first cohorts of their South Africa and U.S. COVID-19 vaccine trials have received their initial doses of the company’s T-cell-based COVID-19 vaccine candidate, hAd5. This candidate is unique in targeting both the spike (S) and nucleocapsid (N) proteins of the SARS-CoV-2 virus. These trials will determine which route combination provides the strongest immune response and long-term immunity, as well as the vaccine candidate’s effectiveness against the growin

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”), Glass, Lewis & Co., LLC (“Glass Lewis”), and Egan-Jones Proxy Services (“Egan-Jones”) have recommended NantKwest stockholders vote “FOR” the pending merger with ImmunityBio. ISS concluded in its February 24, 2021 report: “Both NK and ImmunityBio have engaged in multiple combined clinical trials and collaborative development activities, and this combination has the potential to streamline operations and create strategic and financial synerg

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley Clark, retired U.S. Army General, to the company’s board of directors, effective immediately. With the appointment of Messrs. Brennan and Clark, the company’s board expands to four directors, including Christobel Selecky, who was appointed to the board in August 2020, and Patrick Soon-Shiong, MD, Chairman and CEO of ImmunityBio. All four directors are expected to serve on the combined board of ImmunityBio and NantKwest (Nasdaq: NK) upon completion of the pending merger. “As we exp

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have received FDA authorization to expand Phase I testing of a bivalent hAd5 T-cell COVID-19 vaccine. The FDA authorized the expansion of a currently active multi-cohort trial of the subcutaneous version of the vaccine in order to study the addition of sublingual boosts. The FDA also authorized a second Phase I study that will examine the addition of an oral boost to the subcutaneous prime administration. As a result, the companies will enroll another 105 participants

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately held immunotherapy company, today announced the presentation of encouraging data in non-small cell lung cancer (NSCLC) from the company’s ongoing Phase 2b study, QUILT-3.055 (ClinicalTrials.gov: NCT03228667) at the International Association for the Study of Lung Cancer (IASCL)’s 2020 World Conference on Lung Cancer, Singapore, being held virtually January 28 – 31, 2021. The presentation, titled “QUILT 3.055: a phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors in NSCLC,” highlighted safety and efficacy data from NSCLC patients in Cohort 1 of the study (N=78), which

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, just reported their findings from a follow-up Molecular Dynamics (MD) simulation study of the SARS-CoV-2 spike receptor binding domain (RBD) and its binding to its receptor on human cells, angiotensin-converting enzyme 2 (ACE2). In the first study, “Millisecond-scale molecular dynamics simulation of spike RBD structure reveals evolutionary adaption of SARS-CoV-2 to stably bind ACE2” using exceptionally long-duration millisecond scale MD simulation, ImmunityBio scientists revealed the evolutionary adaptation of spike RBD for binding to ACE2, and the regions of RBD that strongly bind AC

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that NantKwest, Inc. (NASDAQ: NK) (“NantKwest”) and ImmunityBio, Inc. (“ImmunityBio”) have announced that their ongoing Phase 2 clinical trials of a novel combination immunotherapy – which include CytRx’s licensed drug aldoxorubicin – for locally advanced or metastatic pancreatic cancer have produced early indications of increased survival rates for patients with no other approved treatment options. Interim results of the three-cohort trials, kn

8-K - ImmunityBio, Inc. (0001326110) (Filer)

8-K - ImmunityBio, Inc. (0001326110) (Filer)

425 - NantKwest, Inc. (0001326110) (Subject)

10-K - NantKwest, Inc. (0001326110) (Filer)

425 - NantKwest, Inc. (0001326110) (Subject)

425 - NantKwest, Inc. (0001326110) (Subject)

8-K - NantKwest, Inc. (0001326110) (Filer)

425 - NantKwest, Inc. (0001326110) (Subject)

8-K - NantKwest, Inc. (0001326110) (Filer)

8-K - NantKwest, Inc. (0001326110) (Filer)